New shot aims to rally immune system against pancreatic tumors before surgery
NCT ID NCT07024615
Summary
This early-stage study is testing a new drug called ASP2138 for people with pancreatic cancer that can be removed by surgery and has a specific protein called CLDN18.2. Participants receive one injection of ASP2138 two weeks before their scheduled surgery, with the goal of helping the immune system attack the tumor. After surgery, they receive standard chemotherapy for up to six months, and researchers will closely monitor safety and how the body responds.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke University Medical Center - Duke Cancer Center
RECRUITINGDurham, North Carolina, 27710, United States
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.